{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T05:05:19Z","timestamp":1786165519553,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.eplepsyres.2025.107669","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T07:13:43Z","timestamp":1758784423000},"page":"107669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Ganaxolone in Epilepsy: Insights into a Neurosteroid-Based Therapy"],"prefix":"10.1016","volume":"218","author":[{"given":"Giovanni Battista","family":"Dell\u2019Isola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Siciliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"D\u2019Onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Striano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carotenuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Verrotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eplepsyres.2025.107669_bib1","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.13129","article-title":"The fate of interneurons, GABAA receptor subtypes, and perineuronal nets in alzheimer's disease","volume":"33","author":"Ali","year":"2023","journal-title":"Brain Pathol."},{"issue":"7466","key":"10.1016\/j.eplepsyres.2025.107669_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature12439","article-title":"De novo mutations in epileptic encephalopathies","volume":"501","author":"Allen","year":"2013","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.eplepsyres.2025.107669_bib3","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/hmg\/ddy019","article-title":"The female epilepsy protein PCDH19 is a new GABAAR-binding partner that regulates GABAergic transmission as well as migration and morphological maturation of hippocampal neurons","volume":"27","author":"Bassani","year":"2018","journal-title":"Hum. Mol. Genet"},{"issue":"3","key":"10.1016\/j.eplepsyres.2025.107669_bib4","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/S0022-3565(24)36511-5","article-title":"Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor","volume":"280","author":"Carter","year":"1997","journal-title":"J. Pharm. Exp. Ther."},{"issue":"3","key":"10.1016\/j.eplepsyres.2025.107669_bib5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1124\/jpet.119.261735","article-title":"Isobolographic analysis of antiseizure activity of the GABA type a Receptor-Modulating synthetic neurosteroids brexanolone and ganaxolone with tiagabine and midazolam","volume":"372","author":"Chuang","year":"2020","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.eplepsyres.2025.107669_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.780053","article-title":"The broad clinical spectrum of epilepsies associated with protocadherin 19 gene mutation","volume":"12","author":"Dell'Isola","year":"2022","journal-title":"Front Neurol."},{"key":"10.1016\/j.eplepsyres.2025.107669_bib7","doi-asserted-by":"crossref","unstructured":"Dell'Isola G.B., Fattorusso A., Pisani F., Mastrangelo M., Cordelli D.M., Pavone P., Parisi P., Ferretti A., Operto F.F., Elia M., Carotenuto M., Pruna D., Matricardi S., Spezia E., Spalice A., Scorrano G., Savasta S., Prontera P., Di Cara G., Fruttini D., Salpietro V., Striano P., Verrotti A. CDKL5 deficiency-related neurodevelopmental disorders: a multi-center cohort study in Italy. J Neurol. 2024 Aug;271(8):5368-5377. doi: 10.1007\/s00415-024-12421-1. Epub 2024 Jun 14. Erratum in: J Neurol. 2024 Oct 30. doi: 10.1007\/s00415-024-12653-1. PMID: 38874638; PMCID: PMC11319418.","DOI":"10.1007\/s00415-024-12421-1"},{"key":"10.1016\/j.eplepsyres.2025.107669_bib8","author":"European Medicines Agency","year":"2023","journal-title":"Ganaxolone Summ. Prod. Charact."},{"issue":"3","key":"10.1016\/j.eplepsyres.2025.107669_bib9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrn1625","article-title":"Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors","volume":"6","author":"Farrant","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"issue":"9","key":"10.1016\/j.eplepsyres.2025.107669_bib10","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1093\/cercor\/bhr300","article-title":"GABAergic interneuron development and function is modulated by the Tsc1 gene","volume":"22","author":"Fu","year":"2012","journal-title":"Cereb. Cortex"},{"issue":"3","key":"10.1016\/j.eplepsyres.2025.107669_bib11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0165-6147(99)01318-8","article-title":"Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders","volume":"20","author":"Gasior","year":"1999","journal-title":"Trends Pharm. Sci."},{"issue":"7","key":"10.1016\/j.eplepsyres.2025.107669_bib12","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0028-3908(99)00190-2","article-title":"Acute and chronic effects of the synthetic neuroactive steroid, ganaxolone, against the convulsive and lethal effects of pentylenetetrazol in seizure-kindled mice: comparison with diazepam and valproate","volume":"39","author":"Gasior","year":"2000","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.eplepsyres.2025.107669_bib13","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/cpdd.1365","article-title":"Intravenous ganaxolone: pharmacokinetics, pharmacodynamics, safety, and tolerability in healthy adults","volume":"13","author":"Gasior","year":"2024","journal-title":"Clin. Pharm. Drug Dev."},{"issue":"13","key":"10.1016\/j.eplepsyres.2025.107669_bib14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5334\/tohm.760","article-title":"Alcohol and ganaxolone suppress tremor via Extra-Synaptic GABAA receptors in the harmaline model of essential tremor","volume":"18","author":"Handforth","year":"2023","journal-title":"Tremor Other Hyperkinet Mov. (N. Y)"},{"issue":"1","key":"10.1016\/j.eplepsyres.2025.107669_bib15","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.bbr.2012.01.031","article-title":"\"Pharmacological treatment of fragile x syndrome with GABAergic drugs in a knockout mouse model","volume":"229","author":"Heulens","year":"2012","journal-title":"Behav. Brain Res"},{"issue":"2-3","key":"10.1016\/j.eplepsyres.2025.107669_bib16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0014-2999(03)02086-7","article-title":"Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice","volume":"474","author":"Kaminski","year":"2003","journal-title":"Eur. J. Pharm."},{"issue":"2-3","key":"10.1016\/j.eplepsyres.2025.107669_bib17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0920-1211(00)00170-4","article-title":"Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial","volume":"42","author":"Kerrigan","year":"2000","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.eplepsyres.2025.107669_bib18","first-page":"417","article-title":"Marigold trial group. Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Knight","year":"2022"},{"issue":"8","key":"10.1016\/j.eplepsyres.2025.107669_bib19","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s40265-022-01724-0","article-title":"Ganaxolone: first approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.eplepsyres.2025.107669_bib20","first-page":"1187","article-title":"Assessment of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design","volume":"41","author":"Laxer","year":"2000","journal-title":"Ganaxolone Presurgical Study Group. Epilepsia"},{"issue":"1","key":"10.1016\/j.eplepsyres.2025.107669_bib21","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1038\/s41467-023-40800-1","article-title":"Structural insights into opposing actions of neurosteroids on GABAA receptors","volume":"14","author":"Legesse","year":"2023","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.eplepsyres.2025.107669_bib22","first-page":"85","article-title":"A pilot study of the neurosteroid ganaxolone in catamenial epilepsy: clinical experience in two patients","volume":"42","author":"McAuley","year":"2001","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.eplepsyres.2025.107669_bib23","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/ana.26493","article-title":"Ganaxolone versus phenobarbital for neonatal seizure management","volume":"92","author":"Miller","year":"2022","journal-title":"Ann. Neurol."},{"issue":"9","key":"10.1016\/j.eplepsyres.2025.107669_bib24","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/j.1528-1157.1997.tb01486.x","article-title":"Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity","volume":"38","author":"Monaghan","year":"1997","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.eplepsyres.2025.107669_bib25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/epi.17826","article-title":"Long-term treatment with ganaxolone for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: Two-year open-label extension follow-up","volume":"65","author":"Olson","year":"2024","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.eplepsyres.2025.107669_bib26","doi-asserted-by":"crossref","first-page":"s71","DOI":"10.1185\/0300799039117001","article-title":"Acute treatments: some blind alleys","volume":"17","author":"Ramadan","year":"2001","journal-title":"Curr. Med Res Opin."},{"issue":"2","key":"10.1016\/j.eplepsyres.2025.107669_bib27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1124\/jpet.123.001816","article-title":"Neurosteroids as novel anticonvulsants for refractory status epilepticus and medical countermeasures for nerve agents: a 15-Year journey to bring ganaxolone from bench to clinic","volume":"388","author":"Reddy","year":"2024","journal-title":"J. Pharm. Exp. Ther."},{"issue":"3","key":"10.1016\/j.eplepsyres.2025.107669_bib28","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0022-3565(24)39152-9","article-title":"Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy","volume":"294","author":"Reddy","year":"2000","journal-title":"J. Pharm. Exp. Ther."},{"issue":"2-3","key":"10.1016\/j.eplepsyres.2025.107669_bib29","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.eplepsyres.2010.01.009","article-title":"Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling model","volume":"89","author":"Reddy","year":"2010","journal-title":"Epilepsy Res"},{"issue":"3","key":"10.1016\/j.eplepsyres.2025.107669_bib30","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1124\/jpet.118.252155","article-title":"Intravenously administered ganaxolone blocks Diazepam-Resistant Lithium-Pilocarpine-Induced status epilepticus in rats: comparison with allopregnanolone","volume":"368","author":"Saporito","year":"2019","journal-title":"J. Pharm. Exp. Ther."},{"issue":"12","key":"10.1016\/j.eplepsyres.2025.107669_bib31","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1007\/s12035-020-02099-7","article-title":"The Epilepsy-Related protein PCDH19 regulates tonic inhibition, GABAAR kinetics, and the intrinsic excitability of hippocampal neurons","volume":"57","author":"Serratto","year":"2020","journal-title":"Mol. Neurobiol."},{"issue":"4","key":"10.1016\/j.eplepsyres.2025.107669_bib32","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/epi.13705","article-title":"Randomized, double-blind, placebo-controlled phase 2 study of ganaxolone as add-on therapy in adults with uncontrolled partial-onset seizures","volume":"58","author":"Sperling","year":"2017","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.eplepsyres.2025.107669_bib33","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1535-7511.2009.01299.x","article-title":"Infantile spasms: a critical review of emerging animal models","volume":"9","author":"Stafstrom","year":"2009","journal-title":"Epilepsy Curr."},{"issue":"5","key":"10.1016\/j.eplepsyres.2025.107669_bib34","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0387-7604(02)00079-7","article-title":"Infantile spasms, dystonia, and other X-linked phenotypes caused by mutations in aristaless related homeobox gene, ARX","volume":"24","author":"Str\u00f8mme","year":"2002","journal-title":"Brain Dev."},{"key":"10.1016\/j.eplepsyres.2025.107669_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2023.107112","article-title":"Phase 2, placebo-controlled clinical study of oral ganaxolone in PCDH19-clustering epilepsy","volume":"191","author":"Sullivan","year":"2023","journal-title":"Epilepsy Res"},{"issue":"9","key":"10.1016\/j.eplepsyres.2025.107669_bib36","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/epi.17343","article-title":"Intravenous ganaxolone for the treatment of refractory status epilepticus: results from an open-label, dose-finding, phase 2 trial","volume":"63","author":"Vaitkevicius","year":"2022","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.eplepsyres.2025.107669_bib37","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/epi.13999","article-title":"Intramuscular allopregnanolone and ganaxolone in a mouse model of treatment-resistant status epilepticus","volume":"2","author":"Zolkowska","year":"2018","journal-title":"Epilepsia"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121125001706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121125001706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T20:41:33Z","timestamp":1764016893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121125001706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":37,"alternative-id":["S0920121125001706"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2025.107669","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ganaxolone in Epilepsy: Insights into a Neurosteroid-Based Therapy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2025.107669","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107669"}}